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1. Introduction
Pituitary diseases are serious systemic condition reported most likely in patients with an ade-
noma of the pituitary gland because of systemic changes resulting from hyper- or hypofunc-
tion of the pituitary gland. Both medical and surgical treatments have been used in the last 
decades; however, the prediction of post medical and postsurgical treatment is still controver-
sial, even though different criteria for a cure have been suggested, especially the relationship 
between these criteria and the long-term control of the disease [1–3].
The current main treatment options available for pituitary diseases are transsphenoidal 
microsurgical surgery, medical treatment, and radiotherapy. Surgical outcome depends on 
the expertise of the surgeon, tumor size, and extension of the adenoma. Despite surgical 
removal is still the main treatment of pituitary adenomas; however, some patients are not 
cured by surgical treatment and need additional interventions. The main aim of treatment is to 
remove the tumor mass, control the disease by suppressing hormone hyperactivity to normal 
values, reduce morbidity and mortality (especially in acromegaly and Cushing’s patients), 
and eliminate secondary comorbid complications. Such control may be achieved through 
either single or combined surgery, radiotherapy, and/or medical treatment. Continuous and 
long-term monitoring of the disease activity postoperatively, post medical treatment, or post 
radiotherapy is of high priority. However, the prediction of postoperative disease activity is 
a major challenge, and even though different criteria for a cure have been suggested, the rela-
tionship between these criteria and long-term disease control is still controversial. Morbidity 
and mortality rates in untreated and uncontrolled patients are very high due to the effect of 
raised hormone as well as the mass effect in the macroadenomas. Effective and aggressive 
long-term treatment is needed in some cases to normalize these rates. Delay in diagnosis and 
subsequent comorbidities are the main factors influencing the prognosis [3–8].
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Several consensus documents have been published on various aspects of pituitary disease 
management. In the last 20 years, there is a consensus group in each kind of pituitary ade-
noma that reevaluates and updates the guidelines on criteria for cure. One of the important 
problems is the lack of reliable assays, assay standardization, and adequate normative data, 
which are major issues in the interpretation of these biochemical measures; especially these 
factors can lead to major discrepancies in the values obtained in different laboratories [9–12].
The reasons for the heterogeneity among hormone immunoassay results include variable 
calibration, epitope specificity of the chosen antibody, and differences in the specificity of 
antibody recognition of different hormone isoforms circulating in the serum. As a first step to 
improving the interpretation of GH assays, it is strongly recommended that the World Health 
Organization (WHO) international standard (WHO IS 98/574) be used, and the results be 
expressed in mass units (micrograms per liter) [13, 14].
This book provides detailed update on current diagnostic and therapeutic techniques useful 
in the management of pituitary diseases. The contents reflect the multidisciplinary approach 
needed for patients with pituitary diseases with contribution from neurosurgeons, endocri-
nologists, neurologists, radiologists, ophthalmologists, pathologists, and radiation oncolo-
gists. The book focuses on some pituitary diseases especially the most controversial subjects 
in the medical and surgical treatment like dedicated surgical technique by huge pituitary 
adenomas; moreover there is a special chapter about transoral robotic surgery (TORS) with 
the da Vinci system, other important subjects such as management of celiac patients with 
growth failure, pituitary apoplexy, neuro-ophthalmology findings in pituitary disease, and 
hormone secretion in pituitary adenomas: immunohistochemical studies.
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